Facility brings advanced genetic testing capabilities to West Bengal, including prenatal, oncology, and rare disease ...

SeqOnce, a company focused on the research, development, and commercialization of qPCR and NGS genomics tools for the Infectious Disease Research & CLIA Testing Market, has launched their new Measles ...

Linda De Jesus, IDT Vice President and General Manager, Global Head of Commercial.

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...

Tempus AI TEM continues to push the boundaries of precision medicine through a robust pipeline of research and development (R&D) initiatives. In June, the company introduced xM, a liquid biopsy assay ...

Incyte INCY has put up a good performance in the past three months. Shares of the company have gained 9.2% against the industry’s decline of 1.3%. The stock has also outperformed the sector in the ...

Illumina will acquire SomaLogic to expand in proteomics, adding new revenue streams and accelerating tech development in multiomics.

Under the agreement, QIAGEN will design and validate a multimodal panel using its NGS technology on the Illumina NextSeq 550Dx platform. This diagnostic tool will identify genomic alterations in ...

Illumina expects the addition of a high-margin revenue stream, although the deal is expected to close in 2026.

Illumina to acquire SomaLogic, a leader in data-driven proteomics technology, for $350 million: San Diego Tuesday, June 24, 2025, 12:00 Hrs [IST] Illumina, Inc., a global leader i ...

We compared the performance of targeted NGS panels with traditional assays and correlated the mutational landscape with PD-L1 status in Singaporean patients with the National Lung Profiling (NLP) ...

Combines highly complementary proteomics expertise with Illumina's industry-leading product innovation and global market reach Positions Illumina to achieve growth in a large, expanding market ...